Dosimetric comparison of VitalBeam® and HalcyonTM 2.0 for hypofractionated VMAT with simultaneous integrated boost treatment of early‐stage left‐sided breast cancer

Purpose This study compared the quality of treatment plans for early‐stage, left‐sided breast cancer, as planned for and delivered by the HalcyonTM and VitalBeam®. Materials and methods Fifteen patients diagnosed with early‐stage left‐sided breast cancer, who had received VMAT with hypofractionated SIB, were recruited. All cases were planned using HalcyonTM comprising a dual‐layer MLC (DL‐MLC) and VitalBeam® with a Millennium 120 MLC (VB‐MLC). For the PTVs, the quality of coverage (QC), conformity index (CI), and homogeneity index (HI) were calculated for each plan. The dosimetric differences between the two treatment plans were statistically compared using the Wilcoxon signed‐rank test (p